ストックスクリーナーアプリを入手
22.72
1.73%
-0.40
アフターアワーズ：
22.67
-0.05
-0.22%
前日終値:
$23.12
開ける：
$23.2
24時間の取引高:
386.06K
Relative Volume:
1.64
時価総額：
$777.25M
収益：
-
当期純損益:
$-81.05M
株価収益率:
-8.6612
EPS:
-2.6232
ネットキャッシュフロー:
$-68.97M
1週間 パフォーマンス:
+13.37%
1か月 パフォーマンス:
+6.67%
6か月 パフォーマンス:
-22.32%
1年 パフォーマンス:
+23.95%
1日の値動き範囲:
$22.66
$23.77
1週間の範囲:
$19.98
$23.77
52週間の値動き範囲:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
AVBP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
22.72 | 685.62M | 0 | -81.05M | -68.97M | -2.6232 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
Millennium Management LLC Reduces Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Comparing Immutep (NASDAQ:IMMP) and ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of “Buy” by Analysts - Defense World
Cencora Welcomes Lori J. Ryerkerk to Board of Directors - MyChesCo
BNP Paribas Financial Markets Decreases Stock Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,327 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Promising Outlook for ArriVent BioPharma: Buy Rating Justified by Upcoming EGFR PACC Mutant NSCLC Program Updates - TipRanks
Deutsche Bank AG Boosts Stock Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.5% – Here’s What Happened - Defense World
Wall Street Zen Upgrades Atea Pharmaceuticals (NASDAQ:AVIR) to “Hold” - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at Jones Trading - Defense World
JonesResearch Begins Coverage on ArriVent Biopharma (AVBP) with - GuruFocus
ArriVent BioPharma (AVBP) Coverage Initiated with 'Buy' Rating | - GuruFocus
JonesResearch Begins Coverage on ArriVent Biopharma (AVBP) with Optimistic Outlook | AVBP Stock News - GuruFocus
Northern Trust Corp Purchases 10,498 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Northern Trust Corp Boosts Stock Position in AxoGen, Inc. (NASDAQ:AXGN) - Defense World
ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements - MSN
Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress - MyChesCo
When the Price of (AVBP) Talks, People Listen - news.stocktradersdaily.com
Q2 EPS Estimates for ArriVent BioPharma Cut by HC Wainwright - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $40.00 - Defense World
Price T Rowe Associates Inc. MD Has $293,000 Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
B. Riley Lifts Earnings Estimates for ArriVent BioPharma - Defense World
Synnovation Therapeutics Welcomes Rafael G. Amado, M.D., to Board of Directors - MyChesCo
ArriVent BioPharma (AVBP) Receives Price Target Increase by HC W - GuruFocus
Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
ArriVent Biopharma (AVBP) Price Target Increased by Analyst | AV - GuruFocus
ArriVent Biopharma (AVBP) Price Target Increased by Analyst | AVBP Stock News - GuruFocus
Voya Investment Management LLC Acquires Shares of 8,373 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Tower Research Capital LLC TRC Has $43,000 Stock Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ArriVent BioPharma, Inc. SEC 10-Q Report - TradingView
ArriVent Biopharma (AVBP) Projects Financial Stability Through 2 - GuruFocus
ArriVent Biopharma (AVBP) Projects Financial Stability Through 2026 | AVBP Stock News - GuruFocus
ArriVent (AVBP) Advances Oncology Pipeline with Key Milestones Ahead | AVBP Stock News - GuruFocus
ArriVent BioPharma Reports First Quarter 2025 Financial Results - The Manila Times
ArriVent BioPharma (AVBP) Expected to Announce Earnings on Wednesday - Defense World
How to Take Advantage of moves in (AVBP) - news.stocktradersdaily.com
Arrivent Biopharma Inc expected to post a loss of 66 cents a shareEarnings Preview - TradingView
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by Wells Fargo & Company MN - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap Down – Here’s Why - Defense World
Barclays PLC Grows Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Invesco Ltd. Takes Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by JPMorgan Chase & Co. - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update - Defense World
Legal & General Group Plc Purchases 10,783 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Appoints Dr. Merdad Parsey to Board of Directors - MyChesCo
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - The Manila Times
Avantor CEO Michael Stubblefield to Step Down, Search for Successor Underway - MyChesCo
ArriVent BioPharma appoints new board member By Investing.com - Investing.com South Africa
ArriVent BioPharma appoints new board member - Investing.com Australia
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
0.00%
0.54%
大文字化:
|
ボリューム (24 時間):